Parse Biosciences is a pioneering life sciences company based in Seattle, Washington, focused on advancing single-cell sequencing technologies. Founded on innovative scientific principles, the company aims to enhance human health and scientific research through scalable and accessible solutions. Parse's flagship technology, the Evercode™ platform, enables researchers to conduct high-throughput single-cell analyses, facilitating breakthroughs in various fields such as cancer research, immunotherapy, and developmental biology
Founded by Alex Rosenberg, Ph.D., and Charlie H. Kim, Parse Biosciences emerged from technology developed at the University of Washington. The company has experienced rapid growth since its inception, launching its first products in 2021. Parse has expanded its reach significantly, now serving over 1,000 labs globally and establishing a presence in key international markets including Europe, Australia, and South Korea
Parse Biosciences has successfully raised over $100 million in funding through multiple financing rounds. Most recently, the company closed a $50 million Series C funding round led by Soleus Capital, with participation from various investors including Bioeconomy Capital and Janus Henderson Investors. This financial backing is intended to support product expansion and meet increasing demand for its technologies. The company's valuation reflects its growing influence in the genomics market as it continues to innovate within the single-cell sequencing space.
Evercode™ Whole Transcriptome: Enables detailed analysis of gene expression at the single-cell level.
Evercode TCR: Focuses on T-cell receptor sequencing for immunological studies.
Gene Capture: Allows for targeted sequencing of specific genes.
CRISPR Detect: Facilitates the detection of CRISPR modifications.
The recent funding will enable further development of existing technologies and exploration of new applications within genomics, such as immune profiling and pooled CRISPR screens
Parse continually innovates its offerings to meet the evolving needs of researchers. Recent advancements include enhancements to their data analysis tools and the introduction of new applications within their existing product lines. These innovations aim to streamline workflows for researchers and improve the scalability of genomic projects.
People First: Prioritizing the well-being of employees.
Be Bold: Encouraging ambitious goals.
Do the Right Thing: Upholding ethical standards in decision-making.
Take Ownership: Promoting accountability for individual and team outcomes.
Parse's user base includes over 1,000 laboratories worldwide, spanning academic institutions and biotechnology companies. The community around Parse is characterized by active engagement in scientific advancements facilitated by their technologies. Researchers utilize Parse’s products to address complex biological questions, contributing to significant discoveries in fields like cancer treatment and regenerative medicine.
